HopeStage
Back to all studies
CompletedNCT05458479

Fluoxetine safety and effects for depression in adults with Down syndrome

About this titleRead the official source — NCT05458479
Medication studyAges 18–45United States
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

What did participation involve?

The study group receives fluoxetine as a study medication.

Listed locations
LexingtonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 5, 2022
Recruitment status
Completed
Enrollment listed in the registry
4
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT05458479
Official title
Show the full official title

Fluoxetine Treatment of Depression in Adults With Down Syndrome

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Lexington

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Fluoxetine.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies